Tempus AI agreed to acquire Personalis for $1.5 billion, but the stock fell on dilution concerns. Here is why analysts still back the AI diagnostics play.

Tempus AI acquires Personalis to expand its oncology testing portfolio and address a $20B+ MRD detection market with 10% penetration. Personalis brings innovative cancer detection technology, robust ...

Tempus AI, a company that brings artificial intelligence to diagnostics, is growing its capabilities in oncology through a $1.5 billion deal to buy Personalis and its commercialized test for detecting ...

July 20 (Reuters) - Tempus AI said on Monday it would buy Personalis in a deal valued at about $1.5 billion, adding a cancer test to the AI-enabled precision medicine firm's oncology portfolio.

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. Tempus, which is putting a total enterprise value of $1.5 billion on ...

Tempus AI has agreed to acquire the cancer genomics company Personalis in a deal valued at about $1.5 billion, the companies announced July 20. The acquisition builds on a partnership the two ...

AI data company Tempus AI announced it will acquire cancer genomics company Personalis in a transaction valued at approximately $1.5 billion. The acquisition will integrate Personalis' molecular ...

Tempus AI, a technology platform leveraging AI to advance precision medicine and patient care, recently announced its plans to acquire Personalis, a company specializing in early detection of small ...

Tempus AI, a healthcare tech company, is buying cancer testing company Personalis for $1.5 billion—a move that sank both stocks on Monday.

Tempus AI is strengthening its position in minimal residual disease (MDR) testing with the proposed $1.5 billion acquisition of Personalis. The deal is expected to close in late 2026 or early 2027.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Personalis shareholders will ...